fenofibrate has been researched along with Insulin Resistance in 91 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Fifty patients with hypertriglyceridemia in each group were given placebo, n-3 FA 2g+fenofibrate 160mg (combination), or fenofibrate 160mg, respectively daily for 2months." | 9.22 | Vascular and metabolic effects of omega-3 fatty acids combined with fenofibrate in patients with hypertriglyceridemia. ( Han, SH; Koh, KK; Lee, Y; Oh, PC; Sakuma, I; Shin, EK, 2016) |
| "Our study included 41 fenofibrate-treated patients with impaired glucose tolerance allocated to either metformin (3 g daily) or placebo." | 9.17 | Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance. ( Gdula-Dymek, A; Krysiak, R; Okopień, B, 2013) |
| "Omega-3 fatty acids and fenofibrate are both used to treat patients with hypertriglyceridemia." | 9.16 | Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia. ( Han, SH; Koh, KK; Lee, K; Lee, Y; Lim, S; Quon, MJ; Sakuma, I; Shin, EK; Shin, KC, 2012) |
| "This randomized controlled study investigated metformin and fenofibrate, compared with metformin alone, for the treatment of peripheral insulin resistance in patients with simple obesity with hyperinsulinaemia but not diabetes." | 9.15 | Combination therapy with metformin and fenofibrate for insulin resistance in obesity. ( Li, XM; Li, Y; Shi, YQ; Xie, YH; Zhang, NN, 2011) |
| "Fenofibrate therapy significantly reduced pro-inflammatory biomarkers and improved adipocytokines levels and insulin sensitivity in hypertriglyceridemic patients." | 9.15 | Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia. ( Han, SH; Koh, KK; Lee, Y; Lee, YH; Lim, S; Quon, MJ; Sakuma, I; Shin, EK, 2011) |
| " The aim of our study was to assess serum FABP levels in obese patients with type 2 diabetes mellitus (T2DM) before and after 3 months of treatment with PPAR-alpha agonist fenofibrate (F) and to explore the relationship of FABP to biochemical parameters and measures of insulin sensitivity assessed by hyperinsulinemic-isoglycemic clamp." | 9.14 | Serum adipocyte fatty acid binding protein levels in patients with type 2 diabetes mellitus and obesity: the influence of fenofibrate treatment. ( Adamíková, A; Anderlová, K; Doležalová, R; Haluzík, M; Haluzík, MM; Haluzíková, D; Housová, J; Svacina, S, 2009) |
| "In subjects with the MetS, fenofibrate reduces systemic inflammation independent of improvements in lipoprotein metabolism and without changing insulin sensitivity." | 9.14 | Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. ( Belfort, R; Berria, R; Cornell, J; Cusi, K, 2010) |
| " Whole body and liver insulin sensitivity were assessed with a hyperinsulinemic-euglycemic clamp, and insulin signaling and mitochondrial function were measured in muscle biopsies taken before and after approximately 2 weeks of either placebo (PLA) or 5 mg/kg of PPAR-alpha agonist fenofibrate (FEN) treatment, within 3 weeks of injury." | 9.12 | Insulin sensitivity and mitochondrial function are improved in children with burn injury during a randomized controlled trial of fenofibrate. ( Aarsland, A; Cree, MG; Fram, R; Herndon, DN; Morio, B; Qian, T; Sanford, AP; Wolfe, RR; Zwetsloot, JJ, 2007) |
| " Plasma insulin, antiinsulin antibodies, lipid parameters and the insulin sensitivity index (ISI) were measured at entry and after a 3-month therapy with 200 mg micronized fenofibrate daily." | 9.11 | Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. ( Belowski, D; Kalina, M; Kalina, Z; Kochanski, L; Okopien, B; Wysocki, J, 2004) |
| "Improvement in endothelial function is predicted to improve insulin sensitivity, and this may be one mechanism by which fenofibrate decreases the incidence of coronary heart disease." | 9.11 | Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. ( Han, SH; Koh, KK; Quon, MJ; Shin, EK; Yeal Ahn, J, 2005) |
| "These favourable effects of comicronised fenofibrate both on lipid and non lipid parameters, including insulin sensitivity, may confer to this product a particular interest in the treatment of patients with polymetabolic syndrome X." | 9.09 | Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. ( Blane, G; Idzior-Walus, B; Kawalec, E; Rostworowski, W; Sieradzki, J; Wójcik, J; Zarnecki, A; Zdzienicka, A, 2000) |
| "We investigated the effects of fenofibrate on insulin resistance and tissue inflammation in a high-fat diet (HFD)-fed ovariectomized (OVX) C57BL/6J mice, a mouse model of obese postmenopausal women." | 8.31 | Fenofibrate alleviates insulin resistance by reducing tissue inflammation in obese ovariectomized mice. ( Jeon, S; Lee, J; Lee, M; Yoon, M, 2023) |
| " By activating PPARα, the lipid-lowering drug fenofibrate reverses dyslipidemia and improves insulin sensitivity in type 2 diabetes in part by promoting fatty acid oxidation." | 7.83 | Fenofibrate Decreases Insulin Clearance and Insulin Secretion to Maintain Insulin Sensitivity. ( Ghanem, SS; Heinrich, G; Najjar, SM; Oyarce, AM; Patel, PR; Ramakrishnan, SK; Russo, L, 2016) |
| " Ten adolescents with hyperinsulinemia and dyslipidemia received therapy with metformin (500-1500 mg/daily) and micronized fenofibrate (160 mg/daily)." | 7.81 | Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience. ( Kalina, MA; Kalina-Faska, B; Mandera, M; Małecka Tendera, E; Skała-Zamorowska, E; Wilczek, M, 2015) |
| "Fenofibrate is a peroxisome proliferator-activated receptor (PPAR) α ligand that has been widely used as a lipid-lowering agent in the treatment of hypertriglyceridemia." | 7.80 | ABCD2 alters peroxisome proliferator-activated receptor α signaling in vitro, but does not impair responses to fenofibrate therapy in a mouse model of diet-induced obesity. ( Aslibekyan, S; Fourcade, S; Graf, GA; Liang, S; Liu, J; Liu, X; Pujol, A; Schlüter, A, 2014) |
| " Fructose administration resulted in significant increase in body weight, elevations of blood glucose, serum insulin, cholesterol, triglycerides, advanced glycation end products (AGEs), uric acid levels, insulin resistance index and blood pressure compared to control rats." | 7.80 | Ursodeoxycholic acid ameliorates fructose-induced metabolic syndrome in rats. ( Elshazly, SM; Mahmoud, AA, 2014) |
| "The objectives of this study were to determine the effect of osthole on the insulin resistance (IR) in high-fat and high-sucrose-induced fatty liver rats and to investigate its potential mechanisms." | 7.77 | Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats. ( Qi, Z; Wang, H; Xie, M; Xue, J; Zhang, Y, 2011) |
| " Fenofibrate, a lipid-modifying agent that acts as a PPARalpha agonist, may prevent adipocyte hypertrophy and insulin resistance by increasing intracellular lipolysis from adipose tissue." | 7.75 | Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARalpha in high fat diet-induced obese mice. ( Jeong, S; Yoon, M, 2009) |
| "To study the effects of fenofibrate (FF), a peroxisome proliferator activated receptor (PPAR) alpha activator, on the expression of carnitine palmitoyltransferase 1 (CPT-1) mRNA in liver and muscle and its influence on insulin sensitivity." | 7.74 | [Effects of fenofibrate on gene expression of carnitine palmitoyltransferase 1 in liver and skeletal muscle and its influence on insulin sensitivity]. ( Bai, XP; Du, RQ; Li, HL; Lou, DJ; Wang, B; Xiao, JZ; Yang, WY, 2008) |
| "To investigate the effect of transcription-modulating drugs, fenofibrate and isotretinoin, on metabolic profile, insulin sensitivity of adipose and muscle tissues and gene expression in a genetic model of insulin resistance syndrome, polydactylous rat strain (PD/Cub)." | 7.72 | Isotretinoin and fenofibrate induce adiposity with distinct effect on metabolic profile in a rat model of the insulin resistance syndrome. ( Kazdova, L; Kren, V; Krenova, D; Seda, O; Sedova, L, 2004) |
| "Fenofibrate treatment decreased serum triglyceride concentrations, while both blood glucose and glycated hemoglobin increased after three months of fenofibrate administration." | 6.73 | Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes. ( Anderlová, K; Bosanská, L; Dolezalová, R; Haluzík, M; Haluzíková, D; Housová, J; Kremen, J; Skrha, J, 2007) |
| "Fenofibrate treatment significantly lowered T-cho, triglyceride, and LDL-C levels." | 6.73 | Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia. ( Koide, J; Nakanishi, S; Nakashima, R; Oki, K; Yamane, K, 2007) |
| "Fenofibrate is a peroxisome proliferator-activated receptor α agonist widely used in clinical therapy to effectively ameliorate the development of NAFLD, but its mechanism of action is incompletely understood." | 5.91 | Fenofibrate improves hepatic steatosis, insulin resistance, and shapes the gut microbiome via TFEB-autophagy in NAFLD mice. ( Chen, H; Chen, Y; Geng, Z; Huang, M; Li, L; Liu, J; Ma, L; Ma, Y; Wang, D; Wang, H; Wang, X; Wen, D; Zhang, D; Zhu, X; Zou, C, 2023) |
| "Treatment with fenofibrate significantly reduced triglycerides, non-high density lipoprotein cholesterol (non-HDL-C), insulin levels and insulin resistance index (HOMA-IR) in MetS animals." | 5.43 | Fenofibrate Therapy Restores Antioxidant Protection and Improves Myocardial Insulin Resistance in a Rat Model of Metabolic Syndrome and Myocardial Ischemia: The Role of Angiotensin II. ( Carreón-Torres, E; Del Valle-Mondragón, L; Díaz-Díaz, E; Guarner-Lans, V; Ibarra-Lara, L; Rubio-Ruiz, ME; Sánchez-Aguilar, M; Sánchez-Mendoza, A; Soria-Castro, E; Vázquez-Meza, H, 2016) |
| " After establishing a dose-response curve for each drug, the drugs were orally administered for 3 weeks either alone or in combination." | 5.37 | Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice. ( Choi, WS; Kim, IS; Kim, Y; Lee, JJ; Myung, CS; Zhang, WY, 2011) |
| "Insulin sensitivity was unaffected by fenofibrate (P ≥ ." | 5.37 | Fenofibrate administration does not affect muscle triglyceride concentration or insulin sensitivity in humans. ( Bergman, BC; Eckel, RH; Howard, DJ; Hunerdosse, DM; Perreault, L, 2011) |
| " In the future study, we should investigate if higher dosage of vitamin C or other antioxidants would enhance preventive effects of fenofibrate in type 2 diabetes." | 5.34 | Preventive effects of fenofibrate on insulin resistance, hyperglycaemia, visceral fat accumulation in NIH mice induced by small-dose streptozotocin and lard. ( Cai, G; Du, L; Nie, Y; Xie, W; Zhang, Y, 2007) |
| " Fifty patients with hypertriglyceridemia in each group were given placebo, n-3 FA 2g+fenofibrate 160mg (combination), or fenofibrate 160mg, respectively daily for 2months." | 5.22 | Vascular and metabolic effects of omega-3 fatty acids combined with fenofibrate in patients with hypertriglyceridemia. ( Han, SH; Koh, KK; Lee, Y; Oh, PC; Sakuma, I; Shin, EK, 2016) |
| "Fenofibrate is a peroxisome proliferator-activated receptor-α that has been clinically used to treat dyslipidemia and insulin resistance." | 5.19 | Fenofibrate increases serum vaspin by upregulating its expression in adipose tissue. ( Chen, M; Deng, D; Fang, Z; Hu, H; Luo, L; Wang, Y; Xu, M, 2014) |
| "Our study included 41 fenofibrate-treated patients with impaired glucose tolerance allocated to either metformin (3 g daily) or placebo." | 5.17 | Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance. ( Gdula-Dymek, A; Krysiak, R; Okopień, B, 2013) |
| "Fenofibrate-based treatment was associated with improved insulin sensitivity." | 5.16 | Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose. ( Buldak, L; Dulawa-Buldak, A; Labuzek, K; Okopien, B, 2012) |
| "Omega-3 fatty acids and fenofibrate are both used to treat patients with hypertriglyceridemia." | 5.16 | Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia. ( Han, SH; Koh, KK; Lee, K; Lee, Y; Lim, S; Quon, MJ; Sakuma, I; Shin, EK; Shin, KC, 2012) |
| "Fenofibrate therapy significantly reduced pro-inflammatory biomarkers and improved adipocytokines levels and insulin sensitivity in hypertriglyceridemic patients." | 5.15 | Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia. ( Han, SH; Koh, KK; Lee, Y; Lee, YH; Lim, S; Quon, MJ; Sakuma, I; Shin, EK, 2011) |
| "This randomized controlled study investigated metformin and fenofibrate, compared with metformin alone, for the treatment of peripheral insulin resistance in patients with simple obesity with hyperinsulinaemia but not diabetes." | 5.15 | Combination therapy with metformin and fenofibrate for insulin resistance in obesity. ( Li, XM; Li, Y; Shi, YQ; Xie, YH; Zhang, NN, 2011) |
| "Fenofibrate is a peroxisome proliferator-activated receptor-alpha (PPARalpha) activator that has been clinically used to treat dyslipidemia and insulin resistance." | 5.14 | Fenofibrate reduces serum retinol-binding protein-4 by suppressing its expression in adipose tissue. ( Bao, Y; Huang, P; Jia, W; Liu, Y; Lu, J; Wei, L; Wu, H; Xiang, K, 2009) |
| "In subjects with the MetS, fenofibrate reduces systemic inflammation independent of improvements in lipoprotein metabolism and without changing insulin sensitivity." | 5.14 | Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. ( Belfort, R; Berria, R; Cornell, J; Cusi, K, 2010) |
| " The aim of our study was to assess serum FABP levels in obese patients with type 2 diabetes mellitus (T2DM) before and after 3 months of treatment with PPAR-alpha agonist fenofibrate (F) and to explore the relationship of FABP to biochemical parameters and measures of insulin sensitivity assessed by hyperinsulinemic-isoglycemic clamp." | 5.14 | Serum adipocyte fatty acid binding protein levels in patients with type 2 diabetes mellitus and obesity: the influence of fenofibrate treatment. ( Adamíková, A; Anderlová, K; Doležalová, R; Haluzík, M; Haluzík, MM; Haluzíková, D; Housová, J; Svacina, S, 2009) |
| " Whole body and liver insulin sensitivity were assessed with a hyperinsulinemic-euglycemic clamp, and insulin signaling and mitochondrial function were measured in muscle biopsies taken before and after approximately 2 weeks of either placebo (PLA) or 5 mg/kg of PPAR-alpha agonist fenofibrate (FEN) treatment, within 3 weeks of injury." | 5.12 | Insulin sensitivity and mitochondrial function are improved in children with burn injury during a randomized controlled trial of fenofibrate. ( Aarsland, A; Cree, MG; Fram, R; Herndon, DN; Morio, B; Qian, T; Sanford, AP; Wolfe, RR; Zwetsloot, JJ, 2007) |
| " In 12 healthy men, 4-5 wk of rosiglitazone increased insulin sensitivity during insulin infusion but did not change 11beta-HSD1 mRNA or activity in sc adipose tissue, and insulin sensitization was unaffected by glucocorticoid blockade with a combination of metyrapone and RU38486." | 5.12 | Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men. ( Andrew, R; Homer, NZ; Karpe, F; Stimson, RH; Tan, GD; Wake, DJ; Walker, BR, 2007) |
| " Plasma insulin, antiinsulin antibodies, lipid parameters and the insulin sensitivity index (ISI) were measured at entry and after a 3-month therapy with 200 mg micronized fenofibrate daily." | 5.11 | Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. ( Belowski, D; Kalina, M; Kalina, Z; Kochanski, L; Okopien, B; Wysocki, J, 2004) |
| "Improvement in endothelial function is predicted to improve insulin sensitivity, and this may be one mechanism by which fenofibrate decreases the incidence of coronary heart disease." | 5.11 | Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. ( Han, SH; Koh, KK; Quon, MJ; Shin, EK; Yeal Ahn, J, 2005) |
| "These favourable effects of comicronised fenofibrate both on lipid and non lipid parameters, including insulin sensitivity, may confer to this product a particular interest in the treatment of patients with polymetabolic syndrome X." | 5.09 | Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. ( Blane, G; Idzior-Walus, B; Kawalec, E; Rostworowski, W; Sieradzki, J; Wójcik, J; Zarnecki, A; Zdzienicka, A, 2000) |
| "We investigated the effects of fenofibrate on insulin resistance and tissue inflammation in a high-fat diet (HFD)-fed ovariectomized (OVX) C57BL/6J mice, a mouse model of obese postmenopausal women." | 4.31 | Fenofibrate alleviates insulin resistance by reducing tissue inflammation in obese ovariectomized mice. ( Jeon, S; Lee, J; Lee, M; Yoon, M, 2023) |
| "The present work was designed to investigate whether fenofibrate could ameliorate olanzapine deleterious effect on insulin resistance via its effect on fibroblast growth factor-21 (FGF-21)-adiponectin axis without affecting olanzapine antipsychotic effect in postweaning socially isolated reared female rats." | 4.02 | Fenofibrate ameliorates olanzapine's side effects without altering its central effect: emphasis on FGF-21-adiponectin axis. ( Ali, AA; El-Bakly, WM; El-Demerdash, E; El-Kilany, SS; Galal, A, 2021) |
| " By activating PPARα, the lipid-lowering drug fenofibrate reverses dyslipidemia and improves insulin sensitivity in type 2 diabetes in part by promoting fatty acid oxidation." | 3.83 | Fenofibrate Decreases Insulin Clearance and Insulin Secretion to Maintain Insulin Sensitivity. ( Ghanem, SS; Heinrich, G; Najjar, SM; Oyarce, AM; Patel, PR; Ramakrishnan, SK; Russo, L, 2016) |
| " Mice with diet-induced obesity were treated with the PPARγ or PPARα agonist, pioglitazone or fenofibrate, respectively." | 3.83 | Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver. ( Jia, WP; Wang, C; Zhang, ML; Zhong, Y; Zhu, YX, 2016) |
| " Ten adolescents with hyperinsulinemia and dyslipidemia received therapy with metformin (500-1500 mg/daily) and micronized fenofibrate (160 mg/daily)." | 3.81 | Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience. ( Kalina, MA; Kalina-Faska, B; Mandera, M; Małecka Tendera, E; Skała-Zamorowska, E; Wilczek, M, 2015) |
| " Fructose administration resulted in significant increase in body weight, elevations of blood glucose, serum insulin, cholesterol, triglycerides, advanced glycation end products (AGEs), uric acid levels, insulin resistance index and blood pressure compared to control rats." | 3.80 | Ursodeoxycholic acid ameliorates fructose-induced metabolic syndrome in rats. ( Elshazly, SM; Mahmoud, AA, 2014) |
| "Fenofibrate is a peroxisome proliferator-activated receptor (PPAR) α ligand that has been widely used as a lipid-lowering agent in the treatment of hypertriglyceridemia." | 3.80 | ABCD2 alters peroxisome proliferator-activated receptor α signaling in vitro, but does not impair responses to fenofibrate therapy in a mouse model of diet-induced obesity. ( Aslibekyan, S; Fourcade, S; Graf, GA; Liang, S; Liu, J; Liu, X; Pujol, A; Schlüter, A, 2014) |
| " Treatment of high fat diet-induced obese mice with T0901317, an LXR activator, or fenofibrate, the PPARα agonist, or in combination alleviated insulin resistance and improved glucose tolerance." | 3.79 | Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced obese mice. ( Bu, L; Gao, M; Liu, D; Ma, Y, 2013) |
| " In this study, we examined molecular mechanisms that explain differential effects of a PPARα agonist (fenofibrate) and a PPARγ agonist (rosiglitazone) on macrophages during obesity-induced atherogenesis." | 3.79 | PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression. ( Arnould, T; Geeraert, B; Holvoet, P; Hulsmans, M; Tsatsanis, C, 2013) |
| "The objectives of this study were to determine the effect of osthole on the insulin resistance (IR) in high-fat and high-sucrose-induced fatty liver rats and to investigate its potential mechanisms." | 3.77 | Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats. ( Qi, Z; Wang, H; Xie, M; Xue, J; Zhang, Y, 2011) |
| "To observe the effects of fenofibrate on the expression of peroxisome proliferator-activated (PPAR)-gamma coactivator-1α (PGC-1α) in skeletal muscle of rats with insulin resistance (IR) induced by elevated plasma free fatty acid (FFA) levels." | 3.76 | [Effects of fenofibrate on the expression of peroxisome proliferator-activated-gamma coactivator-1α in skeletal muscle of rats infused with intralipid]. ( Bai, XP; Li, HL; Wang, B; Xiao, JZ; Yang, WY, 2010) |
| " These mice had an obese body, lipid metabolic disorder and insulin resistance and were treated orally with 100 mg/kg/day 3'-deoxyadenosine (DA), 15 mg/kg/day rosiglitazone and 150 mg/kg/day fenofibrate, respectively." | 3.76 | Improvement on lipid metabolic disorder by 3'-deoxyadenosine in high-fat-diet-induced fatty mice. ( Liu, Q; Niu, YJ; Tao, RY; Tian, JY; Ye, F; Zhu, HB; Zhu, P, 2010) |
| " In this study, we aimed to: a) evaluate hamster as a model for insulin resistance, hyperlipidemia and atherosclerosis; and b) investigate the effect of a PPAR-α activator, fenofibrate, in this model." | 3.76 | Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster. ( He, S; Srivastava, RA, 2010) |
| " Fenofibrate, a lipid-modifying agent that acts as a PPARalpha agonist, may prevent adipocyte hypertrophy and insulin resistance by increasing intracellular lipolysis from adipose tissue." | 3.75 | Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARalpha in high fat diet-induced obese mice. ( Jeong, S; Yoon, M, 2009) |
| " Here, in an animal model of obesity and insulin resistance, the metabolic response to cevoglitazar, a dual PPARalpha/gamma, was characterized using a combination of in vivo and ex vivo magnetic resonance methodologies and compared to treatment effects of fenofibrate, a PPARalpha agonist, and pioglitazone, a PPARgamma agonist." | 3.75 | Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats. ( Boettcher, BR; Gao, J; Gounarides, JS; Laurent, D, 2009) |
| "To study the effects of fenofibrate (FF), a peroxisome proliferator activated receptor (PPAR) alpha activator, on the expression of carnitine palmitoyltransferase 1 (CPT-1) mRNA in liver and muscle and its influence on insulin sensitivity." | 3.74 | [Effects of fenofibrate on gene expression of carnitine palmitoyltransferase 1 in liver and skeletal muscle and its influence on insulin sensitivity]. ( Bai, XP; Du, RQ; Li, HL; Lou, DJ; Wang, B; Xiao, JZ; Yang, WY, 2008) |
| " The major aim of this study was to establish a novel NASH mouse model accompanied by obesity and insulin resistance, then explore the molecular mechanisms of NASH and evaluate the effects of both the peroxisome proliferator-activated receptor alpha (PPARalpha) agonist fenofibrate and the PPARgamma agonist rosiglitazone in this established NASH model." | 3.74 | The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. ( Cong, WN; Liu, GT; Tao, RY; Tian, JY; Ye, F, 2008) |
| "PPAR-alpha agonist fenofibrate may reverse high-fat diet induced lipid abnormalities, improve insulin sensitivity, and regulate the mRNA expressions of TNF-alpha and adiponectin in adipose tissues." | 3.73 | [Effect of peroxisome proliferator-activated receptor-alpha agonist on adipokines expression in rats fed with high-fat diet]. ( Cheng, H; Huang, B; Li, Y; Liang, Z; Liu, SY, 2006) |
| "To investigate the effect of transcription-modulating drugs, fenofibrate and isotretinoin, on metabolic profile, insulin sensitivity of adipose and muscle tissues and gene expression in a genetic model of insulin resistance syndrome, polydactylous rat strain (PD/Cub)." | 3.72 | Isotretinoin and fenofibrate induce adiposity with distinct effect on metabolic profile in a rat model of the insulin resistance syndrome. ( Kazdova, L; Kren, V; Krenova, D; Seda, O; Sedova, L, 2004) |
| "These findings suggest that pioglitazone and EPA may improve glucose tolerance by directly increasing hepatic insulin sensitivity, while fenofibrate may improve glucose tolerance by improving hepatic glycogen metabolism in the GK rats." | 3.72 | Effects of antihyperlipidemic agents on hepatic insulin sensitivity in perfused Goto-Kakizaki rat liver. ( Horiike, N; Iwai, M; Kanno, S; Matsui, H; Matsuura, B; Minami, H; Onji, M; Tsubouchi, E, 2004) |
| " To determine whether PPARalpha activators also improve insulin sensitivity, we measured the capacity of three PPARalpha-selective agonists, fenofibrate, ciprofibrate, and the new compound GW9578, in two rodent models of high fat diet-induced (C57BL/6 mice) or genetic (obese Zucker rats) IR." | 3.70 | Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. ( Berge, RK; Derudas, B; Fruchart, JC; Gervois, P; Guerre-Millo, M; Herbert, JM; Madsen, L; Poulain, P; Raspé, E; Staels, B; Willson, TM; Winegar, DA, 2000) |
| "Fenofibrate treatment significantly lowered T-cho, triglyceride, and LDL-C levels." | 2.73 | Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia. ( Koide, J; Nakanishi, S; Nakashima, R; Oki, K; Yamane, K, 2007) |
| "Fenofibrate treatment decreased serum triglyceride concentrations, while both blood glucose and glycated hemoglobin increased after three months of fenofibrate administration." | 2.73 | Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes. ( Anderlová, K; Bosanská, L; Dolezalová, R; Haluzík, M; Haluzíková, D; Housová, J; Kremen, J; Skrha, J, 2007) |
| "Recently, nephrolithiasis has been reported to be involved with renal manifestation of metabolic syndrome." | 2.73 | Relationship between insulin resistance and low urinary pH in patients with gout, and effects of PPARalpha agonists on urine pH. ( Inokuchi, T; Ka, T; Kobayashi, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamamoto, T, 2007) |
| "Fenofibrate combined with candesartan improves endothelial function and reduces inflammatory markers to a greater extent than monotherapy in hypertriglyceridemic hypertensive patients." | 2.72 | Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. ( Ahn, JY; Chung, WJ; Han, SH; Kim, JA; Koh, KK; Lee, Y; Quon, MJ; Shin, EK, 2006) |
| "Insulin resistance was assessed by the homeostasis model." | 2.71 | Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. ( Hiukka, A; Hultén, LM; Hurt-Camejo, E; Leinonen, E; Taskinen, MR; Wiklund, O, 2003) |
| "Fenofibrate is a peroxisome proliferator activated receptor alpha agonist that contains both pro and anti-inflammatory properties, and has been used in the treatment of dyslipidemia and diabetes for decades." | 2.48 | Role of the PPAR-α agonist fenofibrate in severe pediatric burn. ( Børsheim, E; Elijah, IE; Finnerty, CC; Herndon, DN; Maybauer, DM; Maybauer, MO, 2012) |
| "Metabolic syndrome is associated with increased cardiovascular risk." | 2.41 | [Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome]. ( Idzior-Waluś, B, 2001) |
| "Fenofibrate is a peroxisome proliferator-activated receptor α agonist widely used in clinical therapy to effectively ameliorate the development of NAFLD, but its mechanism of action is incompletely understood." | 1.91 | Fenofibrate improves hepatic steatosis, insulin resistance, and shapes the gut microbiome via TFEB-autophagy in NAFLD mice. ( Chen, H; Chen, Y; Geng, Z; Huang, M; Li, L; Liu, J; Ma, L; Ma, Y; Wang, D; Wang, H; Wang, X; Wen, D; Zhang, D; Zhu, X; Zou, C, 2023) |
| "Fenofibrate was administered 4 wk after the initiation of the HFD when renal injury was initiated." | 1.46 | Delayed treatment with fenofibrate protects against high-fat diet-induced kidney injury in mice: the possible role of AMPK autophagy. ( Ha, H; Hwang, I; Kang, H; Kim, H; Kim, K; Lee, G; Lee, JH; Sohn, M; Uddin, MJ, 2017) |
| "Treatment with fenofibrate significantly reduced triglycerides, non-high density lipoprotein cholesterol (non-HDL-C), insulin levels and insulin resistance index (HOMA-IR) in MetS animals." | 1.43 | Fenofibrate Therapy Restores Antioxidant Protection and Improves Myocardial Insulin Resistance in a Rat Model of Metabolic Syndrome and Myocardial Ischemia: The Role of Angiotensin II. ( Carreón-Torres, E; Del Valle-Mondragón, L; Díaz-Díaz, E; Guarner-Lans, V; Ibarra-Lara, L; Rubio-Ruiz, ME; Sánchez-Aguilar, M; Sánchez-Mendoza, A; Soria-Castro, E; Vázquez-Meza, H, 2016) |
| "The lipid induced insulin resistance is a major pathophysiologic mechanism underlying glucose intolerance of varying severity." | 1.42 | Fenofibrate Reverses Palmitate Induced Impairment in Glucose Uptake in Skeletal Muscle Cells by Preventing Cytosolic Ceramide Accumulation. ( Bhattacharjee, S; Das, N; Mandala, A; Mukhopadhyay, S; Roy, SS, 2015) |
| "Berardinelli- Seip syndrome is an autosomal recessive disorder characterized by generalized lipoatrophy, extreme insulin resistance with dyslipidemia in childhood and development of diabetes in adolescence." | 1.38 | An unusual cause of delayed puberty: Berardinelli- Seip syndrome. ( Dhull, P; Kumar, KV; Patnaik, SK; Upreti, V, 2012) |
| "Insulin sensitivity was unaffected by fenofibrate (P ≥ ." | 1.37 | Fenofibrate administration does not affect muscle triglyceride concentration or insulin sensitivity in humans. ( Bergman, BC; Eckel, RH; Howard, DJ; Hunerdosse, DM; Perreault, L, 2011) |
| " After establishing a dose-response curve for each drug, the drugs were orally administered for 3 weeks either alone or in combination." | 1.37 | Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice. ( Choi, WS; Kim, IS; Kim, Y; Lee, JJ; Myung, CS; Zhang, WY, 2011) |
| "The interventions were acute hyperinsulinemia during isoglycemic-hyperinsulinemic clamp (n=11 for T2DM and 10 for C), very-low calorie diet (VLCD, n=12 for OB) and 3 months treatment with PPAR-alpha agonist fenofibrate (n=11 for T2DM)." | 1.37 | Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-α agonist treatment. ( Drápalová, J; Haluzík, M; Haluzíková, D; Hanušová, V; Kaválková, P; Lacinová, Z; Mráz, M; Trachta, P, 2011) |
| " In the future study, we should investigate if higher dosage of vitamin C or other antioxidants would enhance preventive effects of fenofibrate in type 2 diabetes." | 1.34 | Preventive effects of fenofibrate on insulin resistance, hyperglycaemia, visceral fat accumulation in NIH mice induced by small-dose streptozotocin and lard. ( Cai, G; Du, L; Nie, Y; Xie, W; Zhang, Y, 2007) |
| "Fenofibrate treatment induced significant reductions in plasma triglycerides (P<0." | 1.34 | Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-alpha agonist treatment. ( Aarsland, A; Chinkes, D; Cree, MG; Newcomer, BR; Paddon-Jones, D; Read, LK; Sheffield-Moore, M; Wolfe, RR, 2007) |
| "Fenofibrate treatment markedly increased circulating resistin levels on both diets and adiponectin levels in chow-fed mice only." | 1.33 | Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels. ( Dolinkova, M; Haluzik, M; Haluzik, MM; Haluzikova, D; Horinek, A; Housa, D; Kumstyrova, T; Lacinova, Z; Vernerova, Z, 2006) |
| "Fenofibrate treatment dramatically reduced fasting blood glucose (P<0." | 1.33 | PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. ( Breyer, M; Cha, DR; Chen, L; Davis, L; Fan, X; Guan, Y; Hwang, MT; Park, CW; Striker, G; Su, D; Wu, J; Zhang, X; Zhang, Y; Zheng, F, 2006) |
| "Fenofibrate treatment improved endothelium-dependent vasorelaxation at only high carbamycholine concentrations (10 microM)." | 1.32 | Fenofibrate lowers adiposity and corrects metabolic abnormalities, but only partially restores endothelial function in dietary obese rats. ( Fatani, S; Naderali, EK; Williams, G, 2004) |
| " The two PPAR-alpha activators, fenofibrate and Wy-14643, were dosed at different concentrations in high-fat fed Sprague-Dawley rats, and the transcriptional responses were examined in liver using cDNA microarrays." | 1.32 | Identification of hepatic transcriptional changes in insulin-resistant rats treated with peroxisome proliferator activated receptor-alpha agonists. ( Fleckner, J; Frederiksen, KS; Sauerberg, P; Wassermann, K; Wulf, EM, 2003) |
| "The treatment of fenofibrate (30 mg." | 1.31 | Amelioration of high fructose-induced metabolic derangements by activation of PPARalpha. ( Kashiwagi, A; Kikkawa, R; Maegawa, H; Nagai, Y; Nakamura, T; Nishio, Y, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.20) | 18.2507 |
| 2000's | 42 (46.15) | 29.6817 |
| 2010's | 43 (47.25) | 24.3611 |
| 2020's | 4 (4.40) | 2.80 |
| Authors | Studies |
|---|---|
| Porcelli, L | 1 |
| Gilardi, F | 2 |
| Laghezza, A | 2 |
| Piemontese, L | 2 |
| Mitro, N | 1 |
| Azzariti, A | 1 |
| Altieri, F | 1 |
| Cervoni, L | 1 |
| Fracchiolla, G | 1 |
| Giudici, M | 1 |
| Guerrini, U | 1 |
| Lavecchia, A | 2 |
| Montanari, R | 1 |
| Di Giovanni, C | 1 |
| Paradiso, A | 1 |
| Pochetti, G | 1 |
| Simone, GM | 1 |
| Tortorella, P | 2 |
| Crestani, M | 1 |
| Loiodice, F | 2 |
| Sblano, S | 1 |
| Cerchia, C | 1 |
| Brunetti, L | 1 |
| Leuci, R | 1 |
| Thomas, A | 1 |
| Genovese, M | 1 |
| Santi, A | 1 |
| Paoli, P | 1 |
| Galal, A | 1 |
| El-Bakly, WM | 1 |
| El-Kilany, SS | 1 |
| Ali, AA | 1 |
| El-Demerdash, E | 1 |
| Zhang, D | 1 |
| Ma, Y | 2 |
| Liu, J | 2 |
| Wang, D | 1 |
| Geng, Z | 1 |
| Wen, D | 1 |
| Chen, H | 1 |
| Wang, H | 3 |
| Li, L | 1 |
| Zhu, X | 1 |
| Wang, X | 1 |
| Huang, M | 1 |
| Zou, C | 1 |
| Chen, Y | 1 |
| Ma, L | 1 |
| Lee, J | 1 |
| Jeon, S | 1 |
| Lee, M | 1 |
| Yoon, M | 2 |
| Blasco, M | 1 |
| Ascaso, JF | 1 |
| Frias, FT | 1 |
| Rocha, KCE | 1 |
| de Mendonça, M | 1 |
| Murata, GM | 1 |
| Araujo, HN | 1 |
| de Sousa, LGO | 1 |
| de Sousa, É | 1 |
| Hirabara, SM | 1 |
| Leite, NC | 1 |
| Carneiro, EM | 1 |
| Curi, R | 1 |
| Silveira, LR | 1 |
| Rodrigues, AC | 1 |
| Upreti, V | 1 |
| Dhull, P | 1 |
| Patnaik, SK | 1 |
| Kumar, KV | 1 |
| Krysiak, R | 1 |
| Gdula-Dymek, A | 1 |
| Okopień, B | 3 |
| Hulsmans, M | 1 |
| Geeraert, B | 1 |
| Arnould, T | 1 |
| Tsatsanis, C | 1 |
| Holvoet, P | 1 |
| Gao, M | 1 |
| Bu, L | 1 |
| Liu, D | 1 |
| Chen, M | 1 |
| Deng, D | 1 |
| Fang, Z | 1 |
| Xu, M | 1 |
| Hu, H | 1 |
| Luo, L | 1 |
| Wang, Y | 1 |
| Sahebkar, A | 1 |
| Chew, GT | 1 |
| Watts, GF | 1 |
| Waldman, B | 1 |
| Jenkins, AJ | 1 |
| Davis, TM | 1 |
| Taskinen, MR | 2 |
| Scott, R | 1 |
| O'Connell, RL | 1 |
| Gebski, VJ | 1 |
| Ng, MK | 1 |
| Keech, AC | 1 |
| Liu, X | 1 |
| Liang, S | 1 |
| Schlüter, A | 1 |
| Fourcade, S | 1 |
| Aslibekyan, S | 2 |
| Pujol, A | 1 |
| Graf, GA | 1 |
| Mahmoud, AA | 1 |
| Elshazly, SM | 1 |
| Kalina, MA | 1 |
| Wilczek, M | 1 |
| Kalina-Faska, B | 1 |
| Skała-Zamorowska, E | 1 |
| Mandera, M | 1 |
| Małecka Tendera, E | 1 |
| Zhang, N | 1 |
| Lu, Y | 1 |
| Shen, X | 1 |
| Bao, Y | 2 |
| Cheng, J | 1 |
| Chen, L | 2 |
| Li, B | 1 |
| Zhang, Q | 1 |
| Bhattacharjee, S | 2 |
| Das, N | 2 |
| Mandala, A | 2 |
| Mukhopadhyay, S | 2 |
| Roy, SS | 2 |
| Zhu, YX | 1 |
| Zhang, ML | 1 |
| Zhong, Y | 1 |
| Wang, C | 1 |
| Jia, WP | 1 |
| Márk, L | 1 |
| Dani, G | 1 |
| Koh, KK | 5 |
| Oh, PC | 1 |
| Sakuma, I | 3 |
| Lee, Y | 4 |
| Han, SH | 5 |
| Shin, EK | 5 |
| Sohn, M | 1 |
| Kim, K | 1 |
| Uddin, MJ | 1 |
| Lee, G | 1 |
| Hwang, I | 1 |
| Kang, H | 1 |
| Kim, H | 1 |
| Lee, JH | 1 |
| Ha, H | 1 |
| Biswas, D | 1 |
| Ghosh, M | 1 |
| Kumar, S | 1 |
| Chakrabarti, P | 1 |
| Ramakrishnan, SK | 1 |
| Russo, L | 1 |
| Ghanem, SS | 1 |
| Patel, PR | 1 |
| Oyarce, AM | 1 |
| Heinrich, G | 1 |
| Najjar, SM | 1 |
| Mukherjee, B | 1 |
| Ibarra-Lara, L | 1 |
| Sánchez-Aguilar, M | 1 |
| Sánchez-Mendoza, A | 1 |
| Del Valle-Mondragón, L | 1 |
| Soria-Castro, E | 1 |
| Carreón-Torres, E | 1 |
| Díaz-Díaz, E | 1 |
| Vázquez-Meza, H | 1 |
| Guarner-Lans, V | 1 |
| Rubio-Ruiz, ME | 1 |
| van der Veen, JN | 1 |
| Lingrell, S | 1 |
| Gao, X | 1 |
| Takawale, A | 1 |
| Kassiri, Z | 1 |
| Vance, DE | 1 |
| Jacobs, RL | 1 |
| Abbasi, F | 1 |
| Chen, YD | 1 |
| Farin, HM | 1 |
| Lamendola, C | 1 |
| Reaven, GM | 1 |
| Wu, H | 1 |
| Wei, L | 1 |
| Lu, J | 1 |
| Huang, P | 1 |
| Liu, Y | 1 |
| Jia, W | 1 |
| Xiang, K | 1 |
| Laurent, D | 1 |
| Gounarides, JS | 1 |
| Gao, J | 1 |
| Boettcher, BR | 1 |
| Zhao, Z | 1 |
| Lee, YJ | 1 |
| Kim, SK | 1 |
| Kim, HJ | 1 |
| Shim, WS | 1 |
| Ahn, CW | 1 |
| Lee, HC | 1 |
| Cha, BS | 1 |
| Ma, ZA | 1 |
| Jeong, S | 1 |
| Arca, M | 1 |
| Cambuli, VM | 1 |
| Montali, A | 1 |
| Sentinelli, F | 1 |
| Filippi, E | 1 |
| Campagna, F | 1 |
| Quagliarini, F | 1 |
| Antonini, R | 1 |
| Romeo, S | 1 |
| Baroni, MG | 1 |
| Forcheron, F | 1 |
| Basset, A | 1 |
| Del Carmine, P | 1 |
| Beylot, M | 1 |
| Belfort, R | 1 |
| Berria, R | 1 |
| Cornell, J | 1 |
| Cusi, K | 1 |
| Fabbrini, E | 1 |
| Mohammed, BS | 1 |
| Korenblat, KM | 1 |
| Magkos, F | 1 |
| McCrea, J | 1 |
| Patterson, BW | 1 |
| Klein, S | 1 |
| Qi, Z | 1 |
| Xue, J | 1 |
| Zhang, Y | 3 |
| Xie, M | 1 |
| Srivastava, RA | 2 |
| He, S | 1 |
| Niu, YJ | 1 |
| Tao, RY | 2 |
| Liu, Q | 1 |
| Tian, JY | 2 |
| Ye, F | 2 |
| Zhu, P | 1 |
| Zhu, HB | 1 |
| Quon, MJ | 4 |
| Lim, S | 2 |
| Lee, YH | 1 |
| Bai, XP | 2 |
| Li, HL | 2 |
| Yang, WY | 2 |
| Xiao, JZ | 2 |
| Wang, B | 2 |
| Perreault, L | 1 |
| Bergman, BC | 1 |
| Hunerdosse, DM | 1 |
| Howard, DJ | 1 |
| Eckel, RH | 2 |
| Chen, W | 1 |
| Zhang, LH | 1 |
| Liu, HY | 1 |
| Zhou, XB | 1 |
| Wang, LL | 1 |
| Choi, WS | 1 |
| Lee, JJ | 1 |
| Kim, Y | 1 |
| Kim, IS | 1 |
| Zhang, WY | 1 |
| Myung, CS | 1 |
| Mráz, M | 1 |
| Lacinová, Z | 2 |
| Kaválková, P | 1 |
| Haluzíková, D | 4 |
| Trachta, P | 1 |
| Drápalová, J | 1 |
| Hanušová, V | 1 |
| Haluzík, M | 4 |
| Li, XM | 1 |
| Li, Y | 2 |
| Zhang, NN | 1 |
| Xie, YH | 1 |
| Shi, YQ | 1 |
| Shin, KC | 1 |
| Lee, K | 1 |
| Rosenblit, PD | 1 |
| Elijah, IE | 1 |
| Børsheim, E | 1 |
| Maybauer, DM | 1 |
| Finnerty, CC | 1 |
| Herndon, DN | 2 |
| Maybauer, MO | 1 |
| Rasouli, N | 1 |
| Kern, PA | 1 |
| Elbein, SC | 1 |
| Sharma, NK | 1 |
| Das, SK | 1 |
| Frazier-Wood, AC | 1 |
| Borecki, IB | 1 |
| Hopkins, PN | 1 |
| Lai, CQ | 1 |
| Ordovas, JM | 1 |
| Straka, RJ | 1 |
| Tiwari, HK | 1 |
| Arnett, DK | 1 |
| Buldak, L | 1 |
| Dulawa-Buldak, A | 1 |
| Labuzek, K | 1 |
| Chan, SM | 1 |
| Sun, RQ | 1 |
| Zeng, XY | 1 |
| Choong, ZH | 1 |
| Watt, MJ | 1 |
| Ye, JM | 1 |
| Leinonen, E | 1 |
| Hurt-Camejo, E | 1 |
| Wiklund, O | 1 |
| Hultén, LM | 1 |
| Hiukka, A | 1 |
| Capell, WH | 1 |
| DeSouza, CA | 1 |
| Poirier, P | 1 |
| Bell, ML | 1 |
| Stauffer, BL | 1 |
| Weil, KM | 1 |
| Hernandez, TL | 1 |
| Frederiksen, KS | 1 |
| Wulf, EM | 1 |
| Wassermann, K | 1 |
| Sauerberg, P | 1 |
| Fleckner, J | 1 |
| Wierzbicki, AS | 1 |
| Mikhailidis, DP | 1 |
| Wray, R | 1 |
| Sedova, L | 1 |
| Seda, O | 1 |
| Krenova, D | 1 |
| Kren, V | 1 |
| Kazdova, L | 1 |
| Wysocki, J | 1 |
| Belowski, D | 1 |
| Kalina, M | 1 |
| Kochanski, L | 1 |
| Kalina, Z | 1 |
| Matsuura, B | 1 |
| Kanno, S | 1 |
| Minami, H | 1 |
| Tsubouchi, E | 1 |
| Iwai, M | 1 |
| Matsui, H | 1 |
| Horiike, N | 1 |
| Onji, M | 1 |
| Dobordzhginidze, LM | 1 |
| Naderali, EK | 1 |
| Fatani, S | 1 |
| Williams, G | 1 |
| Yeal Ahn, J | 1 |
| Chung, WJ | 1 |
| Ahn, JY | 1 |
| Kim, JA | 1 |
| Jahagirdar, R | 1 |
| Azhar, S | 1 |
| Sharma, S | 2 |
| Bisgaier, CL | 1 |
| Park, CW | 1 |
| Zhang, X | 1 |
| Wu, J | 1 |
| Cha, DR | 1 |
| Su, D | 1 |
| Hwang, MT | 1 |
| Fan, X | 1 |
| Davis, L | 1 |
| Striker, G | 1 |
| Zheng, F | 1 |
| Breyer, M | 1 |
| Guan, Y | 1 |
| Haluzik, MM | 2 |
| Dolinkova, M | 1 |
| Housa, D | 1 |
| Horinek, A | 1 |
| Vernerova, Z | 1 |
| Kumstyrova, T | 1 |
| Subramanian, S | 1 |
| DeRosa, MA | 1 |
| Bernal-Mizrachi, C | 1 |
| Laffely, N | 1 |
| Cade, WT | 1 |
| Yarasheski, KE | 1 |
| Cryer, PE | 1 |
| Semenkovich, CF | 1 |
| Sowjanya, A | 1 |
| Kumari, M | 1 |
| Suryaprakash, R | 1 |
| Cynthia, G | 1 |
| Suresh, J | 1 |
| Chakrabarti, R | 1 |
| Anderlová, K | 2 |
| Dolezalová, R | 2 |
| Housová, J | 2 |
| Bosanská, L | 1 |
| Kremen, J | 1 |
| Skrha, J | 2 |
| Cree, MG | 2 |
| Zwetsloot, JJ | 1 |
| Qian, T | 1 |
| Morio, B | 1 |
| Fram, R | 1 |
| Sanford, AP | 1 |
| Aarsland, A | 2 |
| Wolfe, RR | 2 |
| Huang, B | 1 |
| Cheng, H | 1 |
| Liang, Z | 1 |
| Liu, SY | 1 |
| Xie, W | 1 |
| Nie, Y | 1 |
| Du, L | 1 |
| Cai, G | 1 |
| Zeman, M | 1 |
| Vecka, M | 1 |
| Stopka, P | 1 |
| Zahin, M | 1 |
| Tvrzická, E | 1 |
| Stanková, B | 1 |
| Vareka, T | 1 |
| Janíková, L | 1 |
| Zák, A | 1 |
| Wake, DJ | 1 |
| Stimson, RH | 1 |
| Tan, GD | 1 |
| Homer, NZ | 1 |
| Andrew, R | 1 |
| Karpe, F | 1 |
| Walker, BR | 1 |
| Oki, K | 1 |
| Koide, J | 1 |
| Nakanishi, S | 1 |
| Nakashima, R | 1 |
| Yamane, K | 1 |
| Bajaj, M | 1 |
| Suraamornkul, S | 1 |
| Hardies, LJ | 1 |
| Glass, L | 1 |
| Musi, N | 1 |
| DeFronzo, RA | 1 |
| Takahashi, S | 1 |
| Inokuchi, T | 1 |
| Kobayashi, T | 1 |
| Ka, T | 1 |
| Tsutsumi, Z | 1 |
| Moriwaki, Y | 1 |
| Yamamoto, T | 1 |
| Newcomer, BR | 1 |
| Read, LK | 1 |
| Sheffield-Moore, M | 1 |
| Paddon-Jones, D | 1 |
| Chinkes, D | 1 |
| Tanabe, J | 1 |
| Tamasawa, N | 1 |
| Yamashita, M | 1 |
| Matsuki, K | 1 |
| Murakami, H | 1 |
| Matsui, J | 1 |
| Sugimoto, K | 1 |
| Yasujima, M | 1 |
| Suda, T | 1 |
| Adamíková, A | 1 |
| Svacina, S | 1 |
| Tsunoda, M | 1 |
| Kobayashi, N | 1 |
| Ide, T | 1 |
| Utsumi, M | 1 |
| Nagasawa, M | 1 |
| Murakami, K | 1 |
| Du, RQ | 1 |
| Lou, DJ | 1 |
| Cong, WN | 1 |
| Liu, GT | 1 |
| Sindelka, G | 1 |
| Haas, T | 1 |
| Hilgertová, J | 1 |
| Justová, V | 1 |
| Yong, QW | 1 |
| Thavintharan, S | 1 |
| Cheng, A | 1 |
| Chew, LS | 1 |
| Guerre-Millo, M | 1 |
| Gervois, P | 1 |
| Raspé, E | 1 |
| Madsen, L | 1 |
| Poulain, P | 1 |
| Derudas, B | 1 |
| Herbert, JM | 1 |
| Winegar, DA | 1 |
| Willson, TM | 1 |
| Fruchart, JC | 1 |
| Berge, RK | 1 |
| Staels, B | 1 |
| Idzior-Walus, B | 2 |
| Sieradzki, J | 1 |
| Rostworowski, W | 1 |
| Zdzienicka, A | 1 |
| Kawalec, E | 1 |
| Wójcik, J | 1 |
| Zarnecki, A | 1 |
| Blane, G | 1 |
| Nagai, Y | 1 |
| Nishio, Y | 1 |
| Nakamura, T | 1 |
| Maegawa, H | 1 |
| Kikkawa, R | 1 |
| Kashiwagi, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "FGF19 in Obstructive Cholestasis: Unveil the Signal"[NCT05718349] | 81 participants (Anticipated) | Observational | 2017-01-01 | Recruiting | |||
| Effects of Fenofibrate on Metabolic and Reproductive Parameters in Polycystic Ovary Syndrome. A Randomized, Double-Blind, Placebo-Controlled Trial[NCT00884819] | 4 participants (Actual) | Interventional | 2008-12-31 | Terminated (stopped due to Poor recruitment) | |||
| Phase 2 Trial to Examine the Metabolic Effects of Fenofibrate in Burned Patients[NCT00361751] | Phase 2 | 40 participants | Interventional | 2003-05-31 | Completed | ||
| The Role of Mitochondrial Oxidation on Insulin Resistance in Burn Patients Treated With Fenofibrate[NCT00732485] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2008-08-31 | Withdrawn (stopped due to Principal Investigator Changed) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for fenofibrate and Insulin Resistance
| Article | Year |
|---|---|
Control of the overall lipid profile.
Topics: Apolipoproteins B; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemi | 2019 |
New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
Topics: Acetates; Animals; Atherosclerosis; Chalcones; Cholesterol, HDL; Dyslipidemias; Fatty Liver; Fenofib | 2014 |
[Diabetic dyslipidaemia and the atherosclerosis].
Topics: Apolipoprotein A-V; Apolipoproteins A; Apolipoproteins C; Atherosclerosis; Cardiovascular Diseases; | 2016 |
Do persons with diabetes benefit from combination statin and fibrate therapy?
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Dyslipidemias; Female; | 2012 |
Role of the PPAR-α agonist fenofibrate in severe pediatric burn.
Topics: Burns; Fenofibrate; Humans; Hyperglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resist | 2012 |
Drug treatment of combined hyperlipidemia.
Topics: Acute Disease; Clofibric Acid; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hydroxymethyl | 2001 |
[Fibrates: mechanism of action, effect on levels of lipids and risk of coronary events. II. Fenofibrate].
Topics: Adult; Aged; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2004 |
[Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome].
Topics: Cardiovascular Diseases; Clofibrate; Fenofibrate; Hemostasis; Humans; Hyperinsulinism; Hyperlipidemi | 2001 |
26 trials available for fenofibrate and Insulin Resistance
| Article | Year |
|---|---|
Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance.
Topics: Dose-Response Relationship, Drug; Drug Synergism; Female; Fenofibrate; Fibrinogen; Glucose Intoleran | 2013 |
Fenofibrate increases serum vaspin by upregulating its expression in adipose tissue.
Topics: 3T3-L1 Cells; Adipocytes; Adult; Animals; Disease Models, Animal; Dyslipidemias; Fenofibrate; Humans | 2014 |
HDL-C and HDL-C/ApoA-I predict long-term progression of glycemia in established type 2 diabetes.
Topics: Aged; Apolipoprotein A-I; Blood Glucose; Cholesterol, HDL; Cross-Sectional Studies; Diabetes Mellitu | 2014 |
Vascular and metabolic effects of omega-3 fatty acids combined with fenofibrate in patients with hypertriglyceridemia.
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Monitoring; Drug Therapy, | 2016 |
Comparison of three treatment approaches to decreasing cardiovascular disease risk in nondiabetic insulin-resistant dyslipidemic subjects.
Topics: Adult; Aged; Blood Glucose; Caloric Restriction; Cardiovascular Diseases; Cholesterol; Dyslipidemias | 2008 |
Fenofibrate reduces serum retinol-binding protein-4 by suppressing its expression in adipose tissue.
Topics: 3T3-L1 Cells; Adiponectin; Adipose Tissue; Adult; Animals; Diabetes Mellitus, Type 2; Down-Regulatio | 2009 |
Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome.
Topics: Adult; C-Reactive Protein; Double-Blind Method; Fatty Acids, Nonesterified; Female; Fenofibrate; Glu | 2010 |
Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease.
Topics: Adult; Apolipoproteins B; Blood Glucose; Body Composition; Double-Blind Method; Fatty Acids, Noneste | 2010 |
Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia.
Topics: Adipokines; Biomarkers; Cross-Over Studies; Female; Fenofibrate; Hemoglobins; Humans; Hypertriglycer | 2011 |
Combination therapy with metformin and fenofibrate for insulin resistance in obesity.
Topics: Adult; Body Mass Index; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Humans; | 2011 |
Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia.
Topics: Adiponectin; Analysis of Variance; Apolipoprotein A-I; Biomarkers; Blood Glucose; C-Reactive Protein | 2012 |
Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.
Topics: Adipokines; Adiponectin; Adult; Aged; Analysis of Variance; Atorvastatin; Biomarkers; Blood Glucose; | 2012 |
Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes.
Topics: Acute-Phase Reaction; Age Distribution; Aged; Analysis of Variance; Biomarkers; Blood Glucose; Body | 2003 |
Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Fasting; Fatty Acids, Nonesterified; Female; Fenofib | 2003 |
Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome.
Topics: Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Insul | 2004 |
Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia.
Topics: Adiponectin; Blood Flow Velocity; Body Mass Index; Brachial Artery; Cross-Over Studies; Double-Blind | 2005 |
Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe | 2006 |
Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes.
Topics: Adipokines; Adiponectin; Adipose Tissue; Blood Glucose; Body Mass Index; Case-Control Studies; Chole | 2007 |
Insulin sensitivity and mitochondrial function are improved in children with burn injury during a randomized controlled trial of fenofibrate.
Topics: Adolescent; Biopsy; Blood Glucose; Burns; Child; Child, Preschool; Double-Blind Method; Fenofibrate; | 2007 |
Insulin sensitivity and mitochondrial function are improved in children with burn injury during a randomized controlled trial of fenofibrate.
Topics: Adolescent; Biopsy; Blood Glucose; Burns; Child; Child, Preschool; Double-Blind Method; Fenofibrate; | 2007 |
Insulin sensitivity and mitochondrial function are improved in children with burn injury during a randomized controlled trial of fenofibrate.
Topics: Adolescent; Biopsy; Blood Glucose; Burns; Child; Child, Preschool; Double-Blind Method; Fenofibrate; | 2007 |
Insulin sensitivity and mitochondrial function are improved in children with burn injury during a randomized controlled trial of fenofibrate.
Topics: Adolescent; Biopsy; Blood Glucose; Burns; Child; Child, Preschool; Double-Blind Method; Fenofibrate; | 2007 |
[Oxidation stress, insulin resistance and endothelial dysfunction during the treatment of hyperlipidaemia].
Topics: Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Endothelium, Vascular; Fatty Acids, Omega-3; F | 2006 |
Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adult; Aged; Cortisone; Cross-Over Studies; Double-Blin | 2007 |
Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia.
Topics: Adiponectin; Administration, Oral; Adult; Blood Glucose; Cytokines; Fenofibrate; Humans; Hypertrigly | 2007 |
Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
Topics: Adiponectin; AMP-Activated Protein Kinases; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, | 2007 |
Relationship between insulin resistance and low urinary pH in patients with gout, and effects of PPARalpha agonists on urine pH.
Topics: Bezafibrate; Biomarkers; Body Mass Index; Fenofibrate; Gout; Humans; Hydrogen-Ion Concentration; Hyp | 2007 |
Serum adipocyte fatty acid binding protein levels in patients with type 2 diabetes mellitus and obesity: the influence of fenofibrate treatment.
Topics: Biomarkers; Blood Glucose; Body Mass Index; Case-Control Studies; Diabetes Mellitus, Type 2; Fatty A | 2009 |
Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Blood Glucose; Blood | 2000 |
57 other studies available for fenofibrate and Insulin Resistance
| Article | Year |
|---|---|
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.
Topics: Adipocytes; Animals; Antineoplastic Agents; Benzoxazoles; Body Weight; Calorimetry; Cell Differentia | 2012 |
A chemoinformatics search for peroxisome proliferator-activated receptors ligands revealed a new pan-agonist able to reduce lipid accumulation and improve insulin sensitivity.
Topics: Cheminformatics; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands | 2022 |
Fenofibrate ameliorates olanzapine's side effects without altering its central effect: emphasis on FGF-21-adiponectin axis.
Topics: Adiponectin; Adipose Tissue; Animals; Antipsychotic Agents; Female; Fenofibrate; Fibroblast Growth F | 2021 |
Fenofibrate improves hepatic steatosis, insulin resistance, and shapes the gut microbiome via TFEB-autophagy in NAFLD mice.
Topics: Animals; Autophagy; Diet, High-Fat; Fenofibrate; Gastrointestinal Microbiome; Insulin Resistance; Li | 2023 |
Fenofibrate alleviates insulin resistance by reducing tissue inflammation in obese ovariectomized mice.
Topics: Animals; Female; Fenofibrate; Humans; Hyperlipidemias; Inflammation; Insulin Resistance; Liver; Mice | 2023 |
Fenofibrate reverses changes induced by high-fat diet on metabolism in mice muscle and visceral adipocytes.
Topics: Adipocytes; Adipose Tissue, White; Animals; Diet, High-Fat; Energy Metabolism; Fenofibrate; Glucose; | 2018 |
An unusual cause of delayed puberty: Berardinelli- Seip syndrome.
Topics: Administration, Cutaneous; Adolescent; Atorvastatin; Combined Modality Therapy; Diet, Fat-Restricted | 2012 |
PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression.
Topics: Adipocytes; Adiponectin; Animals; Chemokine CCL2; Diet, High-Fat; Fenofibrate; Inflammation; Insulin | 2013 |
Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced obese mice.
Topics: Adipocytes; Adipose Tissue, White; Animals; Blood Glucose; Cell Size; Cholesterol; Diet, High-Fat; F | 2013 |
ABCD2 alters peroxisome proliferator-activated receptor α signaling in vitro, but does not impair responses to fenofibrate therapy in a mouse model of diet-induced obesity.
Topics: Adipocytes; Animals; ATP Binding Cassette Transporter, Subfamily D; ATP-Binding Cassette Transporter | 2014 |
Ursodeoxycholic acid ameliorates fructose-induced metabolic syndrome in rats.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Fenofibrate; Fructose; Glutathione | 2014 |
Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience.
Topics: Adolescent; Carbohydrates; Child; Child, Preschool; Craniopharyngioma; Dyslipidemias; Female; Fenofi | 2015 |
Fenofibrate treatment attenuated chronic endoplasmic reticulum stress in the liver of nonalcoholic fatty liver disease mice.
Topics: Animals; Apoptosis; Blood Glucose; Cholesterol; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Ret | 2015 |
Fenofibrate Reverses Palmitate Induced Impairment in Glucose Uptake in Skeletal Muscle Cells by Preventing Cytosolic Ceramide Accumulation.
Topics: Animals; Carnitine O-Palmitoyltransferase; Cell Line; Ceramides; Cytosol; Diet, High-Fat; Fatty Acid | 2015 |
Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver.
Topics: Animals; Diet, High-Fat; Fatty Liver; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents | 2016 |
Delayed treatment with fenofibrate protects against high-fat diet-induced kidney injury in mice: the possible role of AMPK autophagy.
Topics: Albuminuria; AMP-Activated Protein Kinases; Animals; Autophagy; Diabetic Nephropathies; Diet, High-F | 2017 |
PPARα-ATGL pathway improves muscle mitochondrial metabolism: implication in aging.
Topics: Aging; Animals; Fenofibrate; Insulin Resistance; Lipase; Lipid Metabolism; Mitochondria; Mitochondri | 2016 |
Fenofibrate Decreases Insulin Clearance and Insulin Secretion to Maintain Insulin Sensitivity.
Topics: Animals; Carcinoembryonic Antigen; Fenofibrate; Insulin; Insulin Resistance; Insulin Secretion; Mice | 2016 |
Thioredoxin interacting protein mediates lipid-induced impairment of glucose uptake in skeletal muscle.
Topics: AMP-Activated Protein Kinases; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; | 2016 |
Fenofibrate Therapy Restores Antioxidant Protection and Improves Myocardial Insulin Resistance in a Rat Model of Metabolic Syndrome and Myocardial Ischemia: The Role of Angiotensin II.
Topics: Angiotensin II; Animals; Antioxidants; Catalase; Disease Models, Animal; Fenofibrate; Insulin; Insul | 2016 |
Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine
Topics: Animals; Disease Models, Animal; Endoplasmic Reticulum Stress; Ezetimibe; Fenofibrate; Humans; Insul | 2017 |
Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
Topics: Abdominal Fat; Adiposity; Animals; Body Weight; Dietary Fats; Disease Models, Animal; Fenofibrate; H | 2009 |
Rosiglitazone and fenofibrate improve insulin sensitivity of pre-diabetic OLETF rats by reducing malonyl-CoA levels in the liver and skeletal muscle.
Topics: AMP-Activated Protein Kinases; Animals; Body Weight; Diabetes Mellitus, Experimental; Diet; Fenofibr | 2009 |
Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARalpha in high fat diet-induced obese mice.
Topics: 3T3 Cells; Adipocytes; Animals; Blood Glucose; Body Weight; Cell Enlargement; Dietary Fats; Fenofibr | 2009 |
Serum adiponectin is decreased in patients with familial combined hyperlipidemia and normolipaemic relatives and is influenced by lipid-lowering treatment.
Topics: Adiponectin; Adult; Age Distribution; Atorvastatin; Biomarkers; Cholesterol, HDL; Family; Female; Fe | 2009 |
Lipase maturation factor 1: its expression in Zucker diabetic rats, and effects of metformin and fenofibrate.
Topics: Adipose Tissue; Analysis of Variance; Animals; Blood Glucose; Body Weight; Diabetes Mellitus; Enzyme | 2009 |
Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats.
Topics: Adiponectin; Animals; Blood Glucose; Cnidium; Coumarins; Dietary Fats; Dietary Sucrose; Fatty Liver; | 2011 |
Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster.
Topics: Animals; Aorta; Atherosclerosis; Cholesterol; Cricetinae; Dietary Fats; Fenofibrate; Hyperlipidemias | 2010 |
Improvement on lipid metabolic disorder by 3'-deoxyadenosine in high-fat-diet-induced fatty mice.
Topics: Animals; Area Under Curve; Cordyceps; Deoxyadenosines; Dietary Fats; Disease Models, Animal; Fenofib | 2010 |
[Effects of fenofibrate on the expression of peroxisome proliferator-activated-gamma coactivator-1α in skeletal muscle of rats infused with intralipid].
Topics: Animals; Fatty Acids; Fenofibrate; Gene Expression; Insulin; Insulin Resistance; Male; Muscle, Skele | 2010 |
Fenofibrate administration does not affect muscle triglyceride concentration or insulin sensitivity in humans.
Topics: Aged; Blood Glucose; Body Composition; Female; Fenofibrate; Glucose Tolerance Test; Humans; Hypolipi | 2011 |
Combination of fenofibrate and rosiglitazone synergistically ameliorate dyslipidemia and insulin resistance in mice with MSG metabolic syndrome.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipose Tissue, White; Animals; Animals, Newborn; Blood | 2010 |
Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.
Topics: Animals; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2 | 2011 |
Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-α agonist treatment.
Topics: Acute Disease; Adult; Biomarkers; Blood Glucose; Caloric Restriction; Diabetes Mellitus, Type 2; Fem | 2011 |
Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts.
Topics: Adolescent; Adult; Aged; Female; Fenofibrate; Genome-Wide Association Study; Glucose; Humans; Hypogl | 2012 |
Genome-wide association study indicates variants associated with insulin signaling and inflammation mediate lipoprotein responses to fenofibrate.
Topics: Aged; CD36 Antigens; Female; Fenofibrate; Genetic Variation; Genome-Wide Association Study; Humans; | 2012 |
Activation of PPARα ameliorates hepatic insulin resistance and steatosis in high fructose-fed mice despite increased endoplasmic reticulum stress.
Topics: Animals; Endoplasmic Reticulum Stress; Fatty Acids; Fatty Liver; Fenofibrate; Fructose; Insulin Resi | 2013 |
Identification of hepatic transcriptional changes in insulin-resistant rats treated with peroxisome proliferator activated receptor-alpha agonists.
Topics: Animals; Blotting, Western; Fenofibrate; Insulin Resistance; Liver; Pyrimidines; Rats; Rats, Sprague | 2003 |
Isotretinoin and fenofibrate induce adiposity with distinct effect on metabolic profile in a rat model of the insulin resistance syndrome.
Topics: Adipose Tissue; Animals; Apolipoprotein C-III; Apolipoproteins C; Disease Models, Animal; DNA-Bindin | 2004 |
Effects of antihyperlipidemic agents on hepatic insulin sensitivity in perfused Goto-Kakizaki rat liver.
Topics: Animals; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; Fenofibrate; Glycogen; Hypoglycemic Agent | 2004 |
Fenofibrate lowers adiposity and corrects metabolic abnormalities, but only partially restores endothelial function in dietary obese rats.
Topics: Animals; Blood Glucose; Diet; Endothelial Cells; Fatty Acids, Nonesterified; Fenofibrate; Hypolipide | 2004 |
Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice.
Topics: Adiposity; Animals; Aorta; Coronary Artery Disease; Diet, Atherogenic; Energy Metabolism; Fenofibrat | 2006 |
PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice.
Topics: Albuminuria; Animals; Blood Glucose; Body Weight; Cells, Cultured; Collagen Type I; Diabetes Mellitu | 2006 |
Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels.
Topics: Adiponectin; Adipose Tissue; Animals; Blood Glucose; Diet; Dietary Carbohydrates; Fatty Acids, Nones | 2006 |
PPARalpha activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans.
Topics: Adult; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dexamethasone; Female; Fenofibrate; Fo | 2006 |
Biochemical mechanism of insulin sensitization, lipid modulation and anti-atherogenic potential of PPAR alpha/gamma dual agonist: Ragaglitazar.
Topics: Adipocytes; Animals; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Evaluation, Preclinica | 2006 |
[Effect of peroxisome proliferator-activated receptor-alpha agonist on adipokines expression in rats fed with high-fat diet].
Topics: Adiponectin; Adipose Tissue; Angiotensins; Animals; Dietary Fats; Disease Models, Animal; Fenofibrat | 2006 |
Preventive effects of fenofibrate on insulin resistance, hyperglycaemia, visceral fat accumulation in NIH mice induced by small-dose streptozotocin and lard.
Topics: Animals; Antioxidants; Ascorbic Acid; Blood Glucose; Chemical and Drug Induced Liver Injury; Cholest | 2007 |
Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-alpha agonist treatment.
Topics: Aged; Blood Glucose; Female; Fenofibrate; Humans; Hypolipidemic Agents; Insulin Resistance; Lipids; | 2007 |
Effects of combined PPARgamma and PPARalpha agonist therapy on reverse cholesterol transport in the Zucker diabetic fatty rat.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Blood Glucose; Chole | 2008 |
A novel PPARalpha agonist ameliorates insulin resistance in dogs fed a high-fat diet.
Topics: Adiponectin; Adipose Tissue; Animals; Butyrates; Dietary Fats; DNA, Complementary; Dogs; Dose-Respon | 2008 |
[Effects of fenofibrate on gene expression of carnitine palmitoyltransferase 1 in liver and skeletal muscle and its influence on insulin sensitivity].
Topics: Animals; Blood Glucose; Carnitine O-Palmitoyltransferase; Fenofibrate; Gene Expression Regulation, E | 2008 |
The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
Topics: Animals; Dietary Fats; Disease Models, Animal; Fatty Acids; Fatty Liver; Fenofibrate; Gene Expressio | 2008 |
[Relation between hypertriacylglycerolemia and the action of insulin in type 2 diabetes mellitus].
Topics: Adult; Aged; Clofibrate; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hypertriglyceridemi | 1994 |
The effect of fenofibrate on insulin sensitivity and plasma lipid profile in non-diabetic males with low high density lipoprotein/dyslipidaemic syndrome.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Fenofibrate; Glucose Tolerance Test; Humans; Hyperlipidem | 1999 |
Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity.
Topics: Adipose Tissue; Animals; Butyrates; Clofibrate; Fenofibrate; Hypolipidemic Agents; Insulin Resistanc | 2000 |
Amelioration of high fructose-induced metabolic derangements by activation of PPARalpha.
Topics: Adipose Tissue; Animals; Blood Pressure; Carrier Proteins; CCAAT-Enhancer-Binding Proteins; DNA-Bind | 2002 |